A PHASE 1 OPEN-LABEL, TWO-ARM,DRUG-DRUG INTERACTION STUDY TO EVALUATE THE EFFECT OF ITRACONAZOLE AND RIFAMPIN ON THE PHARMACOKINETICS OF TALAZOPARIB IN PATIENTS WITH ADVANCED SOLID TUMORS

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Talazoparib (Primary) ; Itraconazole; Rifampicin
Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Cervical cancer; Ovarian cancer; Small cell lung cancer; Solid tumours; Triple negative breast cancer
Focus Pharmacokinetics
Sponsors Medivation; Pfizer

26 Nov 2019 Results (n=36) published in the British Journal of Clinical Pharmacology.
25 Jan 2018 Status changed from recruiting to completed.
21 Nov 2017 Planned End Date changed from 23 Dec 2017 to 9 Jan 2018.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com